Pazopanib

Generic Name: Pazopanib

Brand Names: Votrient

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₃N_₇O_₂S

CAS Number: 444731-52-6

Unique Ingredient Identifier: 7RN5DR86CK

Background: Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Indication: Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Associated Conditions: Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer

Associated Therapies: -

Clinical Trials

Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Pazopanib

First Posted Date: 2012-02-02

Last Posted Date: 2017-05-10

Lead Sponsor: Scandinavian Sarcoma Group

Target Recruit Count: 72

Registration Number: NCT01524848

Locations: 🇸🇪
Dept of Oncology, Skane University Hospital, Lund, Sweden
🇸🇪
Dept of Oncology, Norrland University Hospital, Umeå, Sweden
🇸🇪
Dept of Oncology, Linköping University Hospital, Linköping, Sweden

and more 13 locations

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

Phase 4

Completed

Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Clear-cell Metastatic Renal Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2012-01-31

Last Posted Date: 2017-08-23

Lead Sponsor: iOMEDICO AG

Target Recruit Count: 44

Registration Number: NCT01521715

Locations: 🇩🇪
Urolog. Klinik im Waldkrankenhaus St. Marien, Friedrich-Alexander-Universität, Erlangen, Germany
🇩🇪
Universitätsklinikum Essen, Klinik f. Urologie, Essen, Germany
🇩🇪
Medizinisches Versorgungszentrum (MVZ) Osthessen GmbH, Fulda, Germany

and more 5 locations

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Phase 2

Completed

Conditions: Metastatic Liposarcoma
Surgically Unresectable Liposarcoma
Liposarcoma

Interventions: Drug: pazopanib

First Posted Date: 2012-01-10

Last Posted Date: 2017-02-15

Lead Sponsor: Vector Oncology

Target Recruit Count: 42

Registration Number: NCT01506596

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 6 locations

FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer

Phase 2

Completed

Conditions: Advanced Gastric Cancer

Interventions: Drug: Pazopanib
Drug: 5-FU, Oxaliplatin, Leukovorin (FLO)

First Posted Date: 2012-01-04

Last Posted Date: 2019-02-12

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 75

Registration Number: NCT01503372

Locations: 🇩🇪
Charite University medicine, Berlin, Germany

Pazopanib and ARQ 197 for Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Pazopanib
Drug: ARQ 197

First Posted Date: 2011-11-10

Last Posted Date: 2022-07-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT01468922

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Phase 2

Completed

Conditions: Breast Cancer
Breast Neoplasm

Interventions: Drug: Pazopanib

First Posted Date: 2011-11-08

Last Posted Date: 2020-07-08

Lead Sponsor: Hope Rugo, MD

Target Recruit Count: 30

Registration Number: NCT01466972

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Pazopanib
Drug: Trastuzumab (Herceptin®)
Drug: Lapatinib

First Posted Date: 2011-10-19

Last Posted Date: 2016-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 43

Registration Number: NCT01454804

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Pazopanib
Drug: Other anti-VEGFs

First Posted Date: 2011-10-05

Last Posted Date: 2015-03-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01446224

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

Phase 1

Completed

Conditions: Solid Tumors
Thyroid Cancer
Soft-tissue Sarcoma
Cholangiocarcinoma

Interventions: Drug: Pazopanib
Drug: GSK1120212

First Posted Date: 2011-09-22

Last Posted Date: 2018-08-29

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 89

Registration Number: NCT01438554

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Phase 1

Completed

Conditions: Solid Tumors
Advanced Cancers

Interventions: Drug: Pazopanib
Drug: Everolimus

First Posted Date: 2011-09-08

Last Posted Date: 2023-06-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT01430572

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy